Fundamentals to Watch About Relay Therapeutics (RLAY)

By Chris Stiles • Monday, February 20 15:35 • Permanent Link

Shares of Mid-cap basic materials company Relay Therapeutics moved 5.73% this afternoon, and are now trading at $18.45 per share. On the other hand, the average analyst target price for the stock is $35.36. Relay Therapeutics, Inc. is a clinical-stage precision drug company. And its business is unprofitable:

Date Reported	Revenue (k)	Operating Expenses (k)	Operating Margin	YoY Growth
2021-12-31	$30,290	$367,727	-1204.02%	-1683.47%
2020-12-31	$82,654	$138,450	-67.51%	n/a

Based on its trailing earning per share of -3.85, Relay Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -4.79. Its Price to Book (P/B) ratio is 2.116

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.